Project Analyst
University of California, San Francisco
Mai Mehanna received her bachelor’s degree in pharmaceutical sciences in 2010 from Misr International University, Egypt. She earned the American Board Certification in Pharmacotherapy in 2011. Mai worked as a clinical research associate at the Children’s Cancer Hospital from 2012 to 2015. Thereafter, she received a Fulbright scholarship to pursue her master’s degree in Pharmacotherapy and Translational Research which she earned in May 2017 from the University of Florida. There, she studied the field of pharmacogenomics and personalized medicine, and her research work was focused on the role of plasma renin activity biomarker in personalizing antihypertensive drug therapy. In May 2018, she received a graduate assistantship from the University of Florida to pursue her PhD in pharmacogenomics and precision medicine. During her time as a PhD student, Mai studied the metabolomic underpinnings of the factors contributing to variability in BP responses to antihypertensive drugs in European and African American hypertensive patients. She received her PhD degree in Clinical Pharmaceutical Sciences in December 2022. On January 2023, she started working at the Division of Applied Regulatory Sciences (DARS), Center for Drug Evaluation and Research (CDER), U.S. FDA, where she assesses the utility of omics approaches for identifying pharmacodynamic biomarkers for drug development. Mai has several peer-reviewed manuscripts as a first author. She presented numerous abstracts at national research conferences, and her research was selected for several awards.
Thursday, May 29, 2025
11:00 AM - 12:00 PM East Coast USA Time